Cholesterol-Modified Lipid Nanoparticles Enable Spleen-Selective mRNA Delivery

Study Background and Research Question

Messenger RNA (mRNA)-based therapies have emerged as a promising modality for a range of diseases—including cancer, genetic, and autoimmune disorders—due to their capacity to induce transient, cell-specific protein expression. However, the physicochemical properties of mRNA, such as its large size, negative charge, and susceptibility to RNase degradation, pose critical barriers to efficient delivery and translation in vivo (paper). Lipid nanoparticles (LNPs) have enabled clinical translation of mRNA-based interventions, yet most LNP formulations preferentially target the liver after systemic administration, limiting the therapeutic reach to other organs (paper). The spleen, with its unique immunological role and high density of antigen-presenting cells, is an especially attractive target for mRNA vaccines and immune therapeutics, but effective vectors for splenic mRNA expression have remained elusive.

Key Innovation from the Reference Study

To overcome the liver tropism of conventional LNPs and facilitate extrahepatic targeting, the study introduces a new class of particles—ChOlesterol alteREd lipid nanoparticles (CORE LNPs). These nanoparticles leverage rational design and synthesis of cholesterol analogs, particularly those bearing nitrogen-containing heterocyclic motifs, to alter the biodistribution of systemically delivered mRNA. By disrupting cholesterol’s typical interaction with the liver-specific transporter ApoE, the researchers aimed to redirect mRNA expression away from the liver and toward the spleen (paper).

Methods and Experimental Design Insights

The study integrated material synthesis, computational modeling, and systematic experimental optimization:

• Cholesterol analog synthesis: Six distinct heterocyclic cholesterol derivatives were synthesized and characterized computationally for their physicochemical properties and predicted membrane interactions.
• LNP formulation: Each analog was incorporated with standard mRNA LNP excipients (ionizable lipids, phospholipids, PEG-lipids) to yield CORE LNP libraries.
• Design of experiment (DoE): 78 discrete formulations were generated and screened for optimal physical properties, mRNA encapsulation, and stability.
• In vitro assessment: Formulations were evaluated for cellular uptake and endosomal escape in relevant cell lines.
• In vivo studies: Mice received intravenous injections of candidate LNPs encapsulating reporter mRNA. Organ-specific mRNA expression was quantified post-administration, with a focus on splenic versus hepatic expression (paper).

Protocol Parameters

• assay: mRNA encapsulation efficiency | value_with_unit: typically ≥90% | applicability: LNP formulation screening | rationale: High encapsulation is essential for in vivo delivery | source_type: paper
• assay: intravenous mRNA-LNP dose | value_with_unit: 0.5–1 mg/kg | applicability: in vivo organ-targeting studies | rationale: Standard dosing for murine biodistribution | source_type: paper
• assay: mRNA quantification in spleen/liver | value_with_unit: relative luminescence units (RLU) | applicability: organ-specific expression analysis | rationale: Reporter gene readout for biodistribution | source_type: paper
• assay: LNP hydrodynamic diameter | value_with_unit: 60–100 nm | applicability: colloidal stability, biodistribution | rationale: Nanoparticle size influences organ targeting | source_type: paper
• assay: 5-moUTP modification | value_with_unit: 100% substitution | applicability: immunogenicity suppression, translation efficiency | rationale: Reduces innate immune activation and enhances stability | source_type: workflow_recommendation

Core Findings and Why They Matter

The optimized CORE LNPs achieved a significant shift in mRNA expression from the liver to the spleen, in contrast to conventional cholesterol-containing LNPs. In vivo, lead CORE LNPs delivered reporter mRNA that was robustly expressed in splenic tissue with minimal hepatic expression, as confirmed by quantitative imaging and tissue analysis (paper). Importantly, these formulations were well tolerated, with no overt signs of toxicity in treated animals. This organ-selective delivery is highly relevant for immunotherapy and vaccine development, as the spleen’s architecture and cellular composition are pivotal for systemic immune priming. By enabling splenic mRNA expression, CORE LNPs may enhance T cell activation and type I interferon responses—key mechanisms for effective immunization and immune modulation (paper).

Comparison with Existing Internal Articles

Several internal resources discuss advanced mRNA reporters and delivery tools, notably the EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) system. These articles emphasize innovations such as Cap1 capping, 5-moUTP modification to suppress innate immune activation, and Cy5 fluorescent labeling for quantitative tracking (internal; internal). However, while these resources focus on optimizing mRNA structure for delivery, translation, and immune evasion in mammalian systems, the CORE LNP study is distinct in its focus on the carrier’s lipid composition as a determinant of organ-level biodistribution. Combining structurally optimized mRNA (e.g., Cap1 capped, 5-moUTP-modified, fluorescently labeled) with organ-targeted LNPs could, in principle, further enhance the precision and efficacy of mRNA-based therapies—though direct experimental validation of this synergy is recommended (workflow_recommendation).

Limitations and Transferability

Despite its impactful findings, the study is rooted in murine models, and the translation of CORE LNPs’ spleen-targeting capabilities to humans remains to be demonstrated (paper). The immunological microenvironment, blood flow dynamics, and lipid metabolism differ significantly between species, potentially affecting nanoparticle behavior. Moreover, while the study demonstrates a clear shift in biodistribution, the molecular mechanisms underpinning the altered organ selectivity—such as specific interactions with serum proteins or splenic cell subsets—require further elucidation. Additionally, the study does not directly evaluate the performance of structurally modified mRNAs (e.g., with Cap1 or 5-moUTP) within CORE LNPs, nor does it address the stability or translation efficiency of therapeutic payloads beyond the tested reporter systems.

Why this cross-domain matters, maturity, and limitations

The ability to direct mRNA payloads specifically to the spleen opens new possibilities for vaccines and immunotherapeutics that require robust systemic immune activation. However, as the study’s efficacy and safety data are derived from preclinical rodent models, further validation in higher-order animals and, eventually, human trials will be necessary. The modular design principles—combining rationally engineered LNP excipients with advanced mRNA constructs—may be broadly applicable, but each component’s contribution to safety, expression, and immune response must be carefully assessed in each use case (paper).

Research Support Resources

Researchers aiming to evaluate mRNA delivery, translation efficiency, or dual-mode imaging in similar workflows can utilize EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010). This reagent offers a Cap1-capped, 5-moUTP-modified, Cy5-labeled reporter mRNA for quantitative assays in mammalian systems and supports in vivo bioluminescence and fluorescence tracking (source: product_spec). When combined with advanced LNP formulations, such as those described in the CORE LNP study, this tool can facilitate robust evaluation of mRNA delivery, organ targeting, and innate immune activation suppression in research settings.